Can afamelanotide and relugolix be used together?

There is no evidence supporting combined use, and clinically there would be no rationale. Afamelanotide targets skin pigmentation (for EPP), while relugolix suppresses testosterone (for prostate cancer). A patient could theoretically receive both if they had both conditions, but they would be managed independently by different specialists. No drug–drug interaction studies have been published.

Why does relugolix have more clinical trials than afamelanotide?

Relugolix's larger trial portfolio (42 vs 23) reflects its broader applicability and higher patient population. Advanced prostate cancer affects hundreds of thousands of men globally, while EPP affects fewer than 5,000 in developed countries. Larger populations justify more research, and multiple trial arms explore different dosing strategies and comparators.

Is afamelanotide approved in Canada?

No. Afamelanotide is FDA-approved in the US and EMA-authorised in Europe, but Health Canada has not yet approved it. Relugolix, by contrast, is approved in all three jurisdictions (US, EU, and Canada), making it more globally accessible.

Which has fewer side effects?

Neither is inherently safer; they cause different side effects because they work on different systems. Afamelanotide's risks centre on skin changes and nausea; relugolix's on testosterone suppression (hot flashes, erectile dysfunction, bone loss). Choice depends on the condition being treated and individual tolerance for each compound's unique risk profile.

How quickly do these compounds work?

Relugolix achieves testosterone suppression within days (median 29 days to castrate levels). Afamelanotide's effects build over weeks as melanin accumulates in skin; phototoxic reaction reduction becomes apparent after 2–4 weeks of implant placement. Relugolix acts faster, but afamelanotide's slower onset is typical for pigmentation-based therapies.

Afamelanotide vs Relugolix: Key Differences Explained

Afamelanotide and relugolix are both FDA-approved peptides, but they work in completely different biological systems and address different health concerns. Afamelanotide is a melanocyte-stimulating hormone (MSH) analogue used primarily to reduce phototoxicity in patients with erythropoietic protoporphyria (EPP). Relugolix, by contrast, is a gonadotropin-releasing hormone (GnRH) antagonist developed to suppress testosterone in patients with advanced prostate cancer. While both have strong clinical evidence—afamelanotide from 23 clinical trials and relugolix from 42—they're not interchangeable compounds. Understanding their distinct mechanisms, regulatory pathways, and intended populations is essential for informed decision-making.

What Is Afamelanotide?

Afamelanotide is a synthetic analogue of alpha-melanocyte-stimulating hormone (α-MSH), a naturally occurring peptide that regulates skin pigmentation and inflammation. The compound was designed to increase melanin production and protect skin from light-induced damage.

Afamelanotide received FDA approval in 2014 under the brand name Scenesse for a very specific indication: reducing phototoxicity in adults with a confirmed diagnosis of erythropoietic protoporphyria (EPP). EPP is a rare genetic disorder affecting fewer than 5,000 people in the United States, where accumulation of protoporphyrin IX in the skin causes severe pain and blistering upon sun exposure.

The mechanism works by stimulating melanocytes to produce more eumelanin, which provides photoprotection. Clinical trial data showed afamelanotide reduced the mean number of phototoxic reactions from 10.5 per year at baseline to 1.4 per year during treatment, a compelling result for a population with severely limited sun exposure otherwise.

Afamelanotide is delivered as a subcutaneous implant (16 mg) inserted under the skin every 60 days. It's approved in the US and EU but not yet approved by Health Canada.

What Is Relugolix?

Relugolix is a small peptide antagonist of the gonadotropin-releasing hormone (GnRH) receptor. Unlike afamelanotide's niche skin focus, relugolix targets the hypothalamic-pituitary-gonadal (HPG) axis to suppress testosterone production—a critical mechanism in treating advanced prostate cancer.

Relugolix received FDA approval in 2020 under the brand name Orgovyx for patients with advanced prostate cancer. The approval was based on evidence from the HERO trial, which enrolled 934 men and demonstrated that relugolix achieved testosterone suppression in 96.2% of patients by day 29, with sustained suppression throughout the study. This is notably faster than traditional luteinizing hormone-releasing hormone (LHRH) agonists, which typically require 2–3 weeks.

Relugolix is an oral compound taken once daily, making it more convenient than injectable or implantable alternatives. It's approved in the US, EU, and Canada, offering broader geographic accessibility than afamelanotide.

Head-to-Head: Mechanism of Action

These peptides operate in entirely different physiological systems:

Afamelanotide acts on melanocortin receptors (MC1R) on melanocytes, triggering intracellular signalling that increases melanin synthesis. It's a receptor agonist—it activates a biological pathway.

Relugolix blocks GnRH receptors in the pituitary gland, preventing the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), which downstream suppresses testosterone production. It's a receptor antagonist—it inhibits a biological pathway.

The distinction matters: afamelanotide's effect is localized to skin pigmentation, while relugolix's effect is systemic and hormonal. There is virtually no overlap in their biological targets.

Clinical Evidence: Trial Volume and Quality

Both compounds have robust clinical support:

Afamelanotide: 23 clinical trials spanning phototoxicity reduction, skin pigmentation, and investigational uses in other light-sensitive conditions.
Relugolix: 42 clinical trials, the majority focusing on prostate cancer suppression, hormone suppression in other conditions, and dose-ranging studies.

The HERO trial for relugolix involved 934 participants and demonstrated non-inferiority to leuprolide (an LHRH agonist) with faster onset of castration. For afamelanotide, the pivotal PROTEKT trial showed a 76% reduction in the number of phototoxic reaction days in EPP patients.

Both compounds achieved Grade A evidence in their respective indications, meaning high-quality randomized controlled trials demonstrating clinical benefit.

Regulatory Status Comparison

| Aspect | Afamelanotide | Relugolix | |--------|---------------|----------| | FDA | Approved (2014) | Approved (2020) | | EMA | Authorised (2014) | Authorised (2021) | | Health Canada | Not approved | Approved | | Indication | EPP phototoxicity | Advanced prostate cancer | | Formulation | Subcutaneous implant | Oral tablet | | Dosing frequency | Every 60 days | Daily |

Relugolix has achieved broader regulatory acceptance globally, including Canadian approval. Afamelanotide's narrower indication (EPP) limits its addressable population but reflects its specialized therapeutic role.

Key Differences: Patient Suitability

Who Might Use Afamelanotide?

Afamelanotide is designed for the estimated 1,000–5,000 adult patients with confirmed erythropoietic protoporphyria in developed countries. It's suitable for:

Patients with genetically confirmed EPP
Those experiencing recurrent phototoxic reactions (sun-induced pain, blistering)
Adults able to commit to bi-monthly implant replacements
Patients who have failed or are intolerant to other photoprotective measures

The implant procedure requires minor surgery, which may be a barrier for some but is generally well-tolerated.

Who Might Use Relugolix?

Relugolix is intended for men with advanced prostate cancer requiring androgen deprivation therapy (ADT). It's appropriate for:

Patients with metastatic castration-sensitive prostate cancer
Those with locally advanced disease requiring ADT
Men preferring oral therapy over injections or implants
Patients seeking rapid testosterone suppression (onset within days rather than weeks)

Relugolix's broader indication and ease of use (daily pill) make it applicable to thousands of patients annually, unlike afamelanotide's rare-disease focus.

Safety and Tolerability

Afamelanotide's common side effects include skin darkening, nausea, and injection-site reactions. Because it stimulates melanin production, there is theoretical concern about increased mole count or dysplastic nevi, though long-term surveillance data remain evolving. Regular skin monitoring is recommended.

Relugolix's primary adverse effects relate to testosterone suppression: hot flashes, decreased libido, erectile dysfunction, and osteoporosis risk with prolonged use. The HERO trial reported hot flashes in 26% of relugolix-treated patients versus 24% on LHRH agonist, and bone density decline was observed over 48 weeks, consistent with ADT. Cardiovascular risk, a known concern with ADT, was not significantly elevated in the trial.

Neither compound is interchangeable from a safety standpoint; they address different physiological systems and carry different risk profiles.

Cost and Accessibility

Both are specialty pharmaceuticals with significant costs. Afamelanotide's bi-monthly implant procedure adds procedural expenses beyond the drug cost. Relugolix, being oral and widely indicated for prostate cancer, typically has better insurance coverage and fewer access barriers in most healthcare systems.

Afamelanotide's rarity (EPP affects fewer than 5,000 adults in the US) means it's often only available through specialist dermatologists or hematologists. Relugolix is distributed through oncology networks and is more widely available.

The Bottom Line

Afamelanotide and relugolix are not competitors—they exist in separate therapeutic universes. Afamelanotide solves a problem specific to a rare photosensitivity disorder. Relugolix addresses a common oncologic indication affecting tens of thousands of men annually.

If you or a loved one has confirmed EPP and struggles with phototoxic reactions, afamelanotide represents a significant advance. If you have advanced prostate cancer and need testosterone suppression, relugolix offers a convenient, fast-acting oral alternative to traditional hormonal therapies.

For more context, explore how afamelanotide compares to other peptide-based approaches or review how relugolix fits within prostate cancer treatment landscapes. Understanding peptide mechanisms and receptor antagonists can further clarify how these compounds differ at a molecular level.

Afamelanotide vs Relugolix: A Detailed Comparison